# A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

Source: https://onco.cc/trials/nct06925737/  
OnCo record `nct06925737` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Ifinatamab deruxtecan, Docetaxel, Prednisone in prostate cancer, run by Merck Sharp & Dohme LLC, now recruiting.

## Summary

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) is a phase 3 interventional study registered as NCT06925737 by Merck Sharp & Dohme LLC, with 1440 participants planned, started 2025-05-13 and due to reach its primary completion in 2028-06-26. Interventions recorded: Ifinatamab deruxtecan, Docetaxel, Prednisone, Rescue Medication. Conditions listed: Prostate Cancer, Prostatic Neoplasms. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06925737
- Phase: 3
- Setting: A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01)
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 1440

## Sources

- ClinicalTrials.gov NCT06925737: https://clinicaltrials.gov/study/NCT06925737

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/), [Ifinatamab deruxtecan](https://onco.cc/drugs/ifinatamab-deruxtecan/), [Prednisone](https://onco.cc/drugs/prednisone/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct06925737.json